SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Windtree Therapeutics Inc. (WINT)

WINT RSS Feed
Add WINT Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 7/2/2017 8:10:49 PM - Followers: 115 - Board type: Free - Posts Today: 0

The Big Day is Coming!!!!!!!!!!


 The FDA classified the review of the Complete Response as a Class 2 review and established March 6, 2012 as the target action date under the Prescription Drug User Fee Act (PDUFA) to complete its review and potentially grant marketing approval for SURFAXIN.

 





Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant therapies to treat respiratory disorders and diseases based on its KL4 surfactant and capillary aerosol-generating technologies. Its development stage products include Surfaxin, a synthetic, peptide-containing surfactant in phase III clinical trial for the prevention of respiratory distress syndrome in premature infants; Surfaxin LS, a Phase III trial product to improve ease of use for healthcare practitioners; and Aerosurf, an aerosolized KL4 surfactant that has completed first pilot Phase II clinical trial for the treatment of respiratory distress syndrome in premature infants.

The company has a license agreement with Philip Morris USA Inc. to use its capillary aerosolization technology for use with pulmonary surfactants for the respiratory diseases and conditions; and a strategic alliance agreement with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain.

Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.



 

MUST READ!!!!!!!!!!!!!!!!!

  On May 11, 2011, the Company issued a press release highlighting the results of operations for the quarter ended March 31, 2011, and providing an update on its pipeline development as follows:
 
Surfaxin® (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants: The Company is conducting a comprehensive preclinical program to validate its optimized biological activity test (BAT), a key remaining issue that must be addressed to potentially gain U.S. Food and Drug Administration (FDA) marketing approval for Surfaxin in the United States.  The Company has had several interactions with the FDA intended to ensure that the comprehensive preclinical program would ultimately satisfy the FDA.  In January 2011, the Company announced that the FDA had provided guidance to increase the sample size of a specific data set by testing additional Surfaxin batches.  To comply with the FDA's suggestion, the Company has successfully manufactured eight Surfaxin batches and presently plans to manufacture two additional Surfaxin batches for use in the comprehensive preclinical program. The Company presently plans to complete all related analytical testing and concordance studies, and be in a position to file a Surfaxin Complete Response in the third quarter of 2011.
 
Surfaxin LSTM (lyophilized lucinactant) for neonatal RDS :  The Company continues to advance this program. Its plans for 2011 include establishing a commercial-scale manufacturing capability at a cGMP-compliant contract manufacturer with expertise in lyophilized formulations and seeking regulatory guidance from the FDA and the European Medicines Agency (EMA) for the planned clinical development program.
 
Aerosolization Technology :  Recently, at the 2011 Pediatric Academic Societies Annual Meeting (PAS), new data was presented including: (i) a collaborative study indicating that aerosolized KL4 surfactant significantly improved lung function and survival when treating Acute Lung Injury in a well established preclinical model of this severe respiratory condition, (ii) a dose-ranging assessment of aerosolized KL4 surfactant in a widely recognized preclinical model of RDS, demonstrating significant improvement in lung function, lung structural integrity and pulmonary inflammatory mediator profile following treatment with aerosolized KL4 surfactant versus controls, and (iii) a study highlighting the Company's novel patient interface technology intended to increase the efficiency of pulmonary aerosol drug delivery to patients requiring positive pressure ventilatory support.
 
 
2

 

 
 
Regarding the Company's lead aerosolized KL4 surfactant program, Aerosurf® (aerosolized lucinactant for neonatal RDS), data from the preclinical dose ranging assessment study presented at PAS mentioned above suggests that, out of several doses tested, KL4 surfactant delivered via the Company's proprietary capillary aerosol generator during a 20 to 30 minute dosing interval results in the most favorable physiologic outcomes.  This study provides guidance for future clinical dosing strategies for this program. The Company's plans for 2011 include finalizing the clinical and potential commercial design of the capillary aerosol generator, finalizing the clinical and potential commercial design for the novel patient interface, and seeking regulatory guidance in the U.S. and Europe for the planned development program.
 
For the quarter ending June 30, 2011, the Company projects cash outflow of $5.8 million.

 





 

Investor Relations Contacts

John G. Cooper
Executive Vice President, Chief Financial Officer
Discovery Laboratories, Inc.
2600 Kelly Road, Suite 100
Warrington, PA 18976
Tel. 215.488.9490
Fax. 215.488.9391
jcooper@discoverylabs.com


 



As of November 8, 2011, 24,499,497 shares of the registrant's common stock, par value $0.001 per share, were outstanding

As of  May 2, 2011, 24,178,502 shares of the registrant's common stock, par value $0.001 per share, were outstanding.  AutAeeeeee

Authorized 50 Mill

85 BM's 5-15-11



 

 

 

2010-11 Press Releases

 

May 13, 2011 10-Q http://ih.advfn.com/p.php?pid=nmona&article=47677338 

May 13, 2011 http://ih.advfn.com/p.php?pid=nmona&article=47666790       A Brighter Decade Ahead for Biotech - Equity Research on Discovery Laboratories and Mylan Inc   

May 11, 2011 8k http://ih.advfn.com/p.php?pid=nmona&article=47626029     

May 19, 2010
Discovery Labs Achieves Key Milestone Towards Potential Surfaxin® Approval

May 17, 2010
Discovery Labs' KL4 Surfactant Demonstrates Potential Protective Role for Lung Transplantation in Established Preclinical Model

May 14, 2010
Discovery Labs' Phase 2a Aerosurf® Study Published in Journal of Aerosol Medicine and Pulmonary Drug Delivery

May 5, 2010
Surfaxin LSTM Improves Pulmonary Function and Reduces Lung Inflammation in Established Model of Respiratory Distress Syndrome

April 28, 2010
Discovery Labs' KL4 Surfactant Data to be Presented at Pediatric Academic Societies Annual Meeting and American Thoracic Society International Conference

April 27, 2010
Discovery Labs Provides Updates on Surfaxin®, Other Key Programs and First Quarter 2010 Financial Results

March 10, 2010
Discovery Labs Reports Fourth Quarter 2009 Financial Results and Provides Business Update

February 23, 2010
Discovery Labs Announces Completion of $16.5 Million Public Offering

February 18, 2010
Discovery Labs Prices $16.5 Million Public Offering of Common Stock and Warrants

February 17, 2010
Discovery Labs Announces Proposed Public Offering of Common Stock and Warrants

February 16, 2010
Discovery Labs Receives FDA Guidance Regarding Pathway to Potential SURFAXIN® Approval

January 19, 2010
POPG, a Key Component of Discovery Labs KL4 Surfactant, Identified as a Novel Anti-Viral Therapeutic Approach

 



Management Team View Bio

W. Thomas Amick, Interim CEO

Russell Clayton, D.O.
Vice President, Academic and Medical Affairs, Acting Head, Regulatory Affairs and Preclinical Research

Kathryn Cole
Senior Vice President, Human Resources

John G. Cooper
Executive Vice President, Chief Financial Officer

David L. Lopez, C.P.A., Esq.
Executive Vice President, General Counsel

Charles F. Katzer
Senior Vice President, Manufacturing Operations

Thomas F. Miller, Ph.D., MBA
Senior Vice President, Commercialization & Corporate Development

Gerald J. Orehostky
Senior Vice President, Quality Operations

Robert Segal, M.D., F.A.C.P.
Senior Vice President, Medical & Scientific Affairs, Chief Medical Officer

Mary B. Templeton, Esq.
Senior Vice President, Deputy General Counsel

 



Do your own DD & trade smart

(DSCO) Pre-Market Trading     (DSCO) After Hours Trading

(DSCO) Short

Technical Indicators (Barchart) 

Yahoo! Finance (i.e Real-Time)

Last update: June 03,2010

WINT
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
WINT News: (25-NSE) 07/21/2017 09:48:30 AM
WINT News: Current Report Filing (8-k) 07/17/2017 05:10:18 PM
WINT News: Current Report Filing (8-k) 06/30/2017 05:02:38 PM
WINT News: Current Report Filing (8-k) 06/30/2017 06:06:08 AM
WINT News: Additional Proxy Soliciting Materials (definitive) (defa14a) 06/23/2017 08:37:41 AM
PostSubject
#3024   Probably because it was a Friday before a RISK-TAKER 07/02/17 08:10:49 PM
#3023   Then why is it is there no volume today? wodehouse 06/30/17 03:18:06 PM
#3022   Due for a big bounce imo because weak BERKSHIRE AGENT 06/30/17 02:32:52 PM
#3021   It was good news though right? Brooksda 06/30/17 02:28:56 PM
#3020   Hi BA, why is that? adamski 06/30/17 01:35:34 PM
#3019   Buying here. MEGA bounce Commeth BERKSHIRE AGENT 06/30/17 01:26:36 PM
#3018   Thanks for your input. Best of luck big bambino 06/30/17 01:15:41 PM
#3017   Hello Big Bambino, H2R 06/30/17 12:00:18 PM
#3016   I'm in...looks interesting that filters were the issue.. RISK-TAKER 06/30/17 10:41:23 AM
#3015   H2R: are there any other catalyst after this big bambino 06/30/17 10:18:51 AM
#3014   Hi Davidsson10, H2R 06/29/17 05:42:04 PM
#3013   http://www.marketwatch.com/story/windtree-announces-top-line-results-from-aerosu davidsson10 06/29/17 04:08:26 PM
#3012   SoS article after the Lee's agreement: H2R 06/15/17 02:47:26 PM
#3011   Thanks H2R, Great news, when we haven't had big bambino 06/12/17 07:11:51 PM
#3010   Hi wodehouse, H2R 06/12/17 07:10:49 PM
#3009   The Achilles heel for WINT (as for some H2R 06/12/17 07:08:56 PM
#3008   tHOUGHT THIS COMPANY WAS BEING BOUGHT OUT MONTHS AGO? wodehouse 06/12/17 07:02:29 PM
#3007   Non Dilutive Financing: Exclusive Licensing Agreement H2R 06/12/17 06:52:40 PM
#3006   Non Dilutive Financing: Exclusive Licensing Agreement H2R 06/12/17 06:52:16 PM
#3005   Non Dilutive Financing: Exclusive Licensing Agreement H2R 06/12/17 06:52:10 PM
#3004   Top-line AEROSURF Phase 2b On Track for July 2017- H2R 06/01/17 10:05:47 PM
#3003   Successful Completion of Enrollment in AEROSURF® Phase 2b H2R 06/01/17 10:05:09 PM
#3002   https://finance.yahoo.com/news/windtree-receives-sbir-grant-continued-200500106. docprep 05/30/17 06:52:40 PM
#3001   OVER SOLD ! DeafTrader2 05/09/17 11:24:33 AM
#3000   WINT delisted from the Nasdaq to the OTC: Renee 05/04/17 05:07:07 PM
#2999   I picked up another 4k@.79. Was going big bambino 05/04/17 03:56:51 PM
#2998   Getting delisted from the NASDAQ is what is jonnyb 05/04/17 11:24:28 AM
#2997   What is going on with the stock? docprep 05/01/17 09:53:59 PM
#2996   Thanks Padin, H2R 04/12/17 09:05:36 AM
#2995   The product sounds awesome i would love to Padin 04/11/17 11:04:26 PM
#2994   Hi Padin, H2R 04/11/17 10:53:07 PM
#2993   * * $WINT Video Chart 04-11-17 * * ClayTrader 04/11/17 05:17:21 PM
#2992   I work on a level 3 NICU i Padin 04/11/17 04:12:22 PM
#2991   I believe it's between the synthetic makeup and big bambino 04/11/17 04:09:40 PM
#2990   My question would be how does the drug Padin 04/11/17 03:51:53 PM
#2989   Nice job Big Bambino :) H2R 04/11/17 03:15:38 PM
#2988   H2R, big bambino 04/11/17 02:59:42 PM
#2987   H2R, big bambino 04/11/17 02:59:30 PM
#2986   Ph 2b Catalysts: Reuters H2R 04/11/17 10:10:35 AM
#2985   WINT Cash Position H2R 03/31/17 10:13:31 AM
#2984   WINT Catalysts H2R 03/31/17 10:11:05 AM
#2983   Sorry, wrong post. big bambino 03/21/17 11:13:42 PM
#2982   First time I've ever seen shares sold A/H. big bambino 03/21/17 04:53:00 PM
#2981   Windtree Therapeutics, Inc. (NASDAQ:WINT) Files An 8-K Other trendmkr 02/16/17 03:03:00 PM
#2980   Latest Institutional Activity, Top 10 Owners of Windtree lecorb 02/16/17 12:45:34 PM
#2979   WINT: Consensus reco Buy:1 Outperform:1 lecorb 02/16/17 11:47:02 AM
#2978   From the 13G SEC filing today, it looks value1008 02/10/17 05:33:56 PM
#2977   WINT new Presentation , Phase2, September2016,Fast Track designation ash111 02/03/17 12:10:20 PM
#2976   holding mine. there is a reason for those ash111 02/03/17 10:39:53 AM
#2975   No but would love to see another 1M ElCollector 02/03/17 08:22:30 AM
PostSubject